Captozyme Initiates Clinical Study of Nephure™ Oxalate-Reducing Enzyme (BusinessWire)

UF Innovate incubator graduate Captozyme, Inc. announced that it is initiating a prospective double-blind, randomized, placebo controlled, cross-over study, with Nephure™, an oxalate reducing enzyme, to determine the extent to which Nephure vs. placebo reduces urinary oxalate excretion (mg/24 hour) in healthy subjects who are provided a controlled diet. Captozyme is a graduate of both UF Innovate | The Hub and UF Innovate | Sid Martin Biotech.

“Staying true to the science is what we are built on as a company, so we are proud to be taking this important step in further demonstrating how Nephure assists those on a low oxalate diet,” said Helena Cowley, CEO of Captozyme. “With this high-quality study, we aspire to deliver a grade of evidence data that will further strengthen the confidence in our enzymes. With Nephure, it is about giving people freedom back in their foods choices. One less thing to think about for those who avoid oxalates.”

Learn more about Captozyme Initiates Clinical Study of Nephure™ Oxalate-Reducing Enzyme.